TITLE

Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study

AUTHOR(S)
Biancone, L.; Orlando, A.; Kohn, A.; Colombo, E.; Sostegni, R.; Angelucci, E.; Rizzello, F.; Castiglione, F.; Benazzato, I.; Papi, C.; Meucci, G.; Riegler, G.; Petruzziello, C.; Mocciaro, F.; Geremia, A.; Calabrese, E.; Cottone, M.; Pallone, F.
PUB. DATE
February 2006
SOURCE
Gut;Feb2006, Vol. 55 Issue 2, p228
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background and aims: The widespread use of anti-tumour necrosis factor α antibody (Infliximab) in Crohn's disease (CD) raises concerns about a possible cancer risk in the long term. In a matched pair study, we assessed whether Infliximab is associated with an increased risk of neoplasia. Methods: In a multicentre matched pair study, 404 CD patients treated with Infliximab (CD-IFX) were matched with 404 CD patients who had never received Infliximab (CD-C). Cases and controls were matched for sex, age (± 5 years), site of CD, age at diagnosis (± 5 years), immunosuppressant use, and follow up. New diagnoses of neoplasia from April 1999 to October 2004 were recorded. Results: Among the 404 CD-IFX, neoplasia was diagnosed in nine patients (2.22%) while among the 404 CD-C, seven patients developed neoplasia (1.73%) (odds ratio 1.33 (95% confidence interval 0.46–3.84); p = 0.40). The survival curve adjusted far patient year of fallow up showed no differences between CD-IFX and CD-C (p=0.90; log rank test). In the CD-IFX group, there was one cholangiocarcinoma, three breast cancers, one skin cancer, one leukaemia, one laryngeal cancer, and two anal carcinomas. Among the 7/404 (1.73%) CD-C, there were three intestinal adenocarcinomas (two caecum, one rectum), one basalioma, one spinalioma, one non-Hodgkin's lymphoma, and one breast cancer. Age at diagnosis of neaplasla did not differ between groups (CD-IFX v CD-C: median 50 (range 40–70 years) v 45 [27–72); p=0.50). Conclusion: In our multicentre matched pair study, the frequency of a new diagnosis of neoplasia in CD patients treated with Infliximab was comparable with CD patients who had never received Infliximab.
ACCESSION #
19552433

 

Related Articles

  • Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn's disease: an open-label, pilot study. Tursi, A.; Elisei, W.; Picchio, M.; Zampaletta, C.; Pelecca, G.; Faggiani, R.; Brandimarte, G. // Techniques in Coloproctology;Nov2014, Vol. 18 Issue 11, p1041 

    Background: Endoscopic and clinical recurrence of Crohn's disease (CD) appears in up to 80 and 30 % of patients, respectively, 1 year after surgery. Both infliximab (IFX) and adalimumab (ADA) have been demonstrated to be effective in reducing the possibility of recurrence after surgery, but...

  • INFLAMMATORY BOWEL DISEASE.  // Current Medical Literature: Gastroenterology;2004, Vol. 23 Issue 2, p47 

    Presents several abstracts of the articles related to gastroenterology. "A Randomised Placebo Controlled Trial of Pegylated Interferon Alpha in Active Ulcerative Colitis," by H. Tilg, H. Vogelsang, O. Ludwiczek, H. Lochs, A. Kaser, and J. F. Colombel; "The Safety Profile of Infliximab in...

  • Certolizumab pegol. Schiesselman, Lauren S. // Formulary;Jan2008, Vol. 43 Issue 1, p22 

    Despite the variety of medications available to treat Crohn's disease (CD), many patients' symptoms are not adequately controlled with available therapies. Two tumor necrosis factor-alpha (TNF-alpha) inhibitors, infliximab and adalimumab, are approved by FDA for the treatment of...

  • Infliximab: A Review of its Use in Crohn’s Disease and Rheumatoid Arthritis. Siddiqui, M. Asif A.; Scott, Lesley J. // Drugs;2005, Vol. 65 Issue 15, p2179 

    Infliximab (Remicade®) is a chimeric monoclonal antibody against tumour necrosis factor (TNF)-α that has shown efficacy in Crohn's disease and rheumatoid arthritis with a disease-modifying activity and rapid onset of action. It is administered intravenously, generally in a schedule with...

  • The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? D'Haens, Geert R.; Panaccione, Remo; Higgins, Peter D. R.; Vermeire, Severine; Gassull, Miquel; Chowers, Yehuda; Hanauer, Stephen B.; Herfarth, Hans; Hommes, Daan W.; Kamm, Michael; Löfberg, Robert; Quary, A.; Sands, Bruce; Sood, A.; Watermayer, G.; Lashner, Bret; Lémann, Marc; Plevy, Scott; Reinisch, Walter; Schreiber, Stefan // American Journal of Gastroenterology;Feb2011, Vol. 106 Issue 2, p199 

    The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care. Nonetheless, not all patients require biological therapy. Selection of patients depends on clinical characteristics, previous response to other medical therapy, and comorbid conditions. Availability,...

  • Locking the Door to Leukocytes: Use of Integrin Inhibitors for the Treatment of Crohn's Disease. Dryden. Jr, Gerald W. // Clinical Medicine Insights: Therapeutics;2010, Issue 2, p897 

    Inflammatory Bowel Disease (IBD) treatments are rapidly evolving. Current knowledge of the immunopathology responsible for IBD grows on a daily basis. These scientific discoveries are quickly being translated into clinical advances for improved treatment of IBD patients. The breakthrough in...

  • Infliximab: A Review of its use in the Treatment of Pediatric Crohn's Disease. Broder, Arkady; Rosh, Joel R. // Clinical Medicine Insights: Therapeutics;2010, Issue 2, p235 

    The past decade has brought great change to the treatment of pediatric Crohn's disease. The majority of affected patients now receive therapy directed at the underlying immune dysregulation that is associated with this chronic disease. The monoclonal antibodies directed against tumor necrosis...

  • Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: a single-centre experience. Guidi, L.; Ratto, C.; Semeraro, S.; Roberto, I.; De Vitis, I.; Papa, A.; Marzo, M.; Parello, A.; Foglietto, G.; Doglietto, G. B.; Gasbarrini, G. B.; Fedeli, G. // Techniques in Coloproctology;Jun2008, Vol. 12 Issue 2, p111 

    During infliximab treatment of perianal Crohn's disease (CD), the healing of the skin opening precedes fistula tract healing and this contributes to abscess formation and fistula recurrence. The aims of this study were to evaluate the efficacy of combined treatment with infliximab and setons for...

  • A Review of the Use of Infliximab to Manage Cutaneous Dermatoses. Gupta, Aditya K.; Skinner, Alayne R. // Journal of Cutaneous Medicine & Surgery;Mar/Apr2004, Vol. 8 Issue 2, p77 

    Background: Infliximab is a chimeric monoclonal antibody that binds specifically to human tumor necrosis factor-alpha (TNF-α), decreasing the effect of the cytokine in inflammatory diseases. Objective: The aim of this study was to review the efficacy and safety of infliximab in the treatment...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics